Casdin Capital

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Biopharmaceutical research and development company that's an affiliate of Clover Health

Remix Therapeutics Inc. engages in the biotech research and development business. It discovers and develops various novel therapeutic RNA processing modulators to target various undruggable disease drivers. The company also offers biology platform to identify and prioritize targets with therapeutically-tractable intervention points in RNA processing. Its REMseq platform validates targets and chemical matter discovery and optimization. The company was founded in 2018 and is based in Cambridge, Massachusetts.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.

Arzeda Corporation, founded in 2008 and based in Seattle, Washington, specializes in the development and commercialization of innovative enzymes and specialty chemical products. The company leverages advanced computational enzyme design technology to create designer proteins and enzymes tailored for diverse applications in polymers, pharmaceuticals, and industrial chemicals. By focusing on biocatalysis, Arzeda aims to provide clients with high-performance, cost-effective, and sustainable solutions that enhance their products. The company's expertise in synthetic biology positions it as a leader in the field, enabling the development of a robust portfolio that addresses the growing demand for advanced chemical products.

Celsius Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that focuses on the development and research of innovative drugs. Established in 2017, the company utilizes single-cell genomic analysis and machine learning to gain insights into the cellular ecosystems of diseases. This approach allows Celsius Therapeutics to identify critical biomarkers that can enhance patient care and contribute to the creation of transformative medicines. The company's commitment to advancing the understanding of complex diseases positions it as a key player in the biotechnology sector.

Deepcell, Inc. is a company based in Mountain View, California, focused on advancing diagnostic technologies through a non-invasive approach. Founded in 2015, it has developed a microfluidic imaging platform that leverages artificial intelligence to classify cells by their visual features. This technology allows for the isolation of viable cells based on their morphological characteristics, facilitating detailed genetic health assessments from standard blood samples. By enabling insights at the single-cell level, Deepcell aims to improve the diagnosis and treatment of various diseases, offering researchers a valuable alternative to invasive diagnostic methods.

22seventy bio is an immuno-oncology cell therapy company that discovers and develops cancer therapies. The company combines a deep knowledge of cancer cell biology and genetics with an understanding of the immune response to cancer to advance its pipeline. It was established in Cambridge, Massachusetts in 2021.

Molecular Assemblies, Inc. is a San Diego-based company that specializes in enzymatic DNA synthesis technology, which allows for the precise reading and writing of DNA. Founded in 2013, the company targets multiple markets, including life sciences, industrial applications, information storage, nanotechnology, and DNA electronics. Its innovative approach is inspired by natural processes and focuses on producing long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner. The company boasts a strong executive and scientific team and holds an extensive intellectual property portfolio. It has garnered investments from various notable entities, highlighting its potential to advance products in industrial synthetic biology, personalized therapeutics, and precision diagnostics.

Creyon Bio is a pre-clinical stage company focused on revolutionizing drug development through a data-driven approach. The company specializes in creating proprietary datasets that enhance the design and engineering of RNA-based medicines, particularly precision oligonucleotide-based therapies. By leveraging advanced machine learning models, Creyon Bio aims to identify essential design rules and engineering principles that facilitate the development of safe and effective oligonucleotide-based medicines. This innovative methodology is intended to streamline the drug development process, ultimately helping the healthcare sector reduce costs associated with bringing new therapies to market.

Volta Labs, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on engineering and developing tools for biological automation. Founded in 2018, the company specializes in creating scalable automation solutions for genetic engineering, aiming to enhance efficiency and precision in biological research and applications.

Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Fluidigm Corporation develops and markets innovative technologies and tools for life sciences research globally. The company specializes in integrated fluidic circuits that control fluids at the nanoscale, enabling a range of applications in biological research. Its product offerings include analytical systems such as the Helios CyTOF system, the Hyperion imaging system, and the Biomark HD system, along with various assays and reagents designed for immuno-oncology and genetic analysis. Fluidigm also provides preparatory instruments and single-cell microfluidics, such as the C1 and Polaris systems. The company serves a diverse clientele, including academic institutions, clinical research laboratories, biopharmaceutical, biotechnology, and agricultural biotechnology companies, focusing on non-diagnostic and non-clinical applications. Established in 1999 as Mycometrix Corporation, it adopted the name Fluidigm Corporation in 2001 and is headquartered in South San Francisco, California.

Innovation in healthcare is hindered by the time and cost of bringing new products to market. Verana Health is partnering with medical associations to build a regulatory-grade data platform for health care innovation that utilizes specialty clinical data sets. Verana Health’s platform enables physicians and industry to work together towards their shared goal of accelerating the availability of better treatments and cures for patients. Learn more at veranahealth.com.

Maze Therapeutics is a operator of a biotechnology firm intended to focused on translating genetic insights into new medicines. The company's translating genetic insights into new medicines by utilizing an approach that combines the analysis of large-scale human genetics data, functional genomics and an array of drug discovery approaches.and its also reveals modifier genes that confer protection and provides deeper understanding of the target biology and how these targets can be targeted with drug therapies, enabling patients with protection against diseases.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

Oxford NanoImaging Limited develops and manufactures microscope. It offers Nanoimager, a single-molecule fluorescence microscope which enables researchers to detect biomolecules, such as protein markers for disease or pathogenic bacteria, and viruses at single copy numbers with single-molecule imaging, 3D, and dual-color super-resolution functionality. It also offers Förster Resonance Energy Transfer microscopy technology that reports distances in real time; direct stochastic optical reconstruction microscopy (dSTORM); and photoactivated localization microscopy (PALM) technology based microscope. Oxford NanoImaging Limited was incorporated in 2016 and is based in London, United Kingdom. The company has additional office in Menlo Park, California.

Apella is a technology company that brings modern engineering to improve surgery. It was founded in 2020 and is headquartered in San Francisco, California.

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

Depixus SAS is a biotechnology company based in Paris, France, focused on the development of advanced technology for extracting genetic and epigenetic information from single molecules of DNA and RNA. Its main product, SIMDEQ™ (SIngle-molecule Magnetic DEtection and Quantification), enables fast, accurate, and cost-effective analysis of genomes and epigenetic modifications. Initially developed at École Normale Supérieure by prominent researchers, SIMDEQ™ allows for the identification, counting, full sequencing, and epityping of millions of individual DNA molecules with high precision. The technology has broad applications in the life sciences and medical fields, facilitating real-time analysis of biomolecular interactions and supporting researchers in uncovering new biological pathways, understanding disease mechanisms, and advancing precision medicine. With substantial validation completed, Depixus is moving towards platform optimization and commercialization to enhance its offerings in these critical areas.

Meiogenix SAS operates as a biotech company that develops breeding and genomic technologies. It offers SpiX technology, which modulates the process of homologous recombination in the genome by increasing its frequency in cold regions and PhoeniX, which is a non-GM method that induces meiotic recombination in hybrid diploid (or polyploid) yeast cells without the need to go through the entire process of meiosis. The company helps to develop new products to address global food and industrial challenges. The company was incorporated in 2010 and is based in Paris, France.

Exai Bio is a next-generation liquid biopsy company. Exai bio proprietary RNA and artificial intelligence-based liquid biopsy platform deliver clinical insights into cancer biology to enable the earliest, most accurate diagnosis of cancer.

Nplex Biosciences is a biotechnology company based in the United States that specializes in proteomic technology. The company has developed a platform that utilizes DNA nanotechnology to understand, detect, and treat diseases. Nplex offers a range of instruments and automation tools for measuring multiple proteins from blood samples, providing cost-effective solutions for protein data analysis. Its technology integrates seamlessly with industry-standard cytometers, enabling high-throughput analysis and the development of custom protein panels. Nplex aims to enhance existing instruments and workflows while facilitating automation in proteomic research and applications.

Lunit Inc. is a South Korean company that specializes in developing advanced algorithms for medical image analysis and general object detection using machine learning technology. The firm focuses on areas such as digital chest X-ray, digital mammography, digital pathology, and fundus photography. By leveraging cutting-edge deep learning techniques, Lunit aims to assist physicians in making accurate and efficient clinical decisions. The company has demonstrated its expertise in image recognition, having ranked among the top five in the ImageNet Challenge, a prominent competition in the field. Lunit's technology is notable for its ability to utilize weakly labeled data, enhancing its pattern recognition capabilities. Supported by significant venture capital investments, Lunit is actively engaged in large-scale research collaborations with major university hospitals in South Korea, reflecting its strong reception within the medical community.

Stilla Technologies is a Paris-based European Biotechnology company that focuses on accelerating the development of next-generation genetic tests by providing a ground-breaking and flexible digital PCR (dPCR) solution: the Naica System. Taking advantage of cutting-edge microfluidic innovations, Stilla aims to make dPCR a lab commodity to all Life Sciences areas: research, therapeutics, and all the “omics”.

Chroma Medicine is a new genomic medicine company working on epigenetic editing. Chroma Medicine is pioneering a new class of genomic medicines that harness epigenetics, nature’s innate mechanism for gene regulation, to revolutionize the treatment of genetically driven diseases.

Qloudlab is a pioneering company that has developed Sceptre, the world's first touchscreen-based biosensor platform designed for Point-of-Care diagnostics. This modular and cost-effective technology allows for the simultaneous performance of various tests, including blood, urine, saliva, and skin tests, all on a single mobile platform. By integrating advancements in smartphone technology, healthcare, and cloud solutions, Qloudlab aims to enhance the accessibility and efficiency of diagnostic testing. The company focuses on simplifying the testing process for both patients and healthcare professionals, making healthcare more adaptable to individual lifestyles.

Diseases of the neuromuscular junction have profound health effects including paralysis, breathing and swallowing difficulties. Amplo Biotechnology plans to develop multiple, potentially curative, Adeno-Associated Viral (AAV) therapies for the neuromuscular junction with an initial focus on congenital myasthenic syndromes. Amplo’s lead program, AAV-Dok7, was developed by Professor Yuji Yamanashi's group of the Institute of Medical Science at the University of Tokyo, and is applicable to multiple rare, severe diseases.

Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Thyme Care is a Nashville TN-based provider of oncology care management solutions.

Ginkgo Bioworks, founded in 2008 and based in Boston, Massachusetts, specializes in biological engineering by designing, developing, and licensing custom microbes and organisms. The company focuses on discovering and producing a variety of molecules for applications in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. Additionally, Ginkgo Bioworks offers probiotic bacteria aimed at protecting against harmful infections and creates libraries of molecules for various uses. Its market reach includes sectors such as cultured ingredients, carbon mitigation, probiotics, and natural product discovery.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Established in 2019, ROME Therapeutics is pioneering the exploration of the repeatome, which consists of extensive regions of genetic material previously considered "junk DNA." The company has identified several drug targets and is actively advancing multiple discovery programs. To facilitate its research, ROME has assembled a team of experts across various disciplines, including oncology, immunology, virology, and machine learning, to harness this uncharted area of biology for therapeutic advancements.

Xcell Biosciences, Inc. is a life science start-up based in San Francisco, California, founded in 2012. The company focuses on developing innovative technology to capture, grow, and analyze cancer cells directly from patient blood samples. Its proprietary systems allow for precise control of primary cell phenotype and function, which enhances the development and production of cell therapies. By optimizing the efficacy and persistence of immune cell therapies, Xcell Biosciences aims to contribute significantly to advancements in cancer treatment.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

NanoCellect Biomedical, Inc. develops innovative flow cytometry and cell sorting technology aimed at enhancing the capabilities of life science researchers in cellular analysis, molecular diagnostics, and personalized medicine. Founded in 2009 and based in San Diego, California, the company offers the WOLF Cell Sorter, which utilizes a closed fluid-path microfluidic cartridge to facilitate cell sorting while minimizing biohazard risks and shear stress commonly associated with traditional methods. By making flow cytometry more affordable and accessible, NanoCellect aims to support biomedical researchers in analyzing and isolating cells efficiently, thereby promoting significant advancements in drug discovery and diagnostics. The company's technology is designed to provide rapid, objective, and quantitative data on individual cells, empowering scientists to conduct essential research with greater ease and precision.

Zentera Therapeutics is a biopharmaceutical company.

T-knife is a developer of T cell receptors intended for T cell therapy of cancer.The company uses a humanized TCR mice platform to carry human TCRαβ gene loci and recombine a broad repertoire of human TCRs, enabling the efficient generation and virtual selection of cell receptors for any human tumor antigen.

Genomatica, Inc. delivers manufacturing processes to produce intermediate and basic chemicals from renewable feedstocks. The company’s proprietary biotechnology platform allows the company to create fermentation-based manufacturing processes and to engineer the enabling microorganisms that drive the conversion of renewable feedstocks into intermediate and basic chemicals. It is developing a pipeline of manufacturing processes for the production of 20 intermediate and basic chemicals, including butanediol and butadiene. The company intends to offer its chemical products to large consumer products or chemical companies. Genomatica, Inc. was founded in 1998 and is headquartered in San Diego, California.

Sema4 is a patient-centered predictive health company dedicated to advancing the diagnosis, treatment, and prevention of disease. With their innovative Sema4 Health Intelligence Platform, they’re using advanced network analysis to build better models of human health and deliver personalized insights for patients.

TMRW Life Sciences is a developer of a cryo-storage platform intended to improve the success rates of assisted reproductive technology. The company's platform offers an in-clinic robotic storage system and a fully digital chain of custody from clinic to offsite longterm storage, continuous remote and local monitoring and electronically integrated processes characterized by digital health signals received from every oocyte and embryo daily, enabling clients to streamline embryology lab operations, eliminate manual steps and integrates digital quality control.

Hexagon Bio, Inc. is a biotechnology company based in Menlo Park, California, that specializes in mining genomic data from fungal genomes to develop targeted small molecule therapeutics for diseases with unmet medical needs. Founded in 2016, the company leverages a proprietary platform that integrates data science, synthetic biology, and automation to discover and engineer novel drugs. By focusing on evolutionarily refined molecules and their corresponding protein targets, Hexagon Bio aims to identify and develop new medicines from the global metagenome, ultimately striving to enhance patient outcomes through innovative therapeutic solutions.

23andMe, Inc. is a consumer genetics company that provides DNA analysis services through home-based saliva collection kits, enabling users to explore their ancestry, inherited traits, and health insights. Founded in 2006 and headquartered in Sunnyvale, California, the company offers various services, including Health + Ancestry and Ancestry + Traits, which provide insights into a person's genetic background and over 30 trait reports. 23andMe aims to help individuals understand the implications of their genetic information while also catering to researchers by offering categorized and searchable data. The company was co-founded by Linda Avey and Anne Wojcicki and has positioned itself as a significant player in the growing biotechnology and healthcare sectors.

Born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. The extraordinary team at Nautilus represents a wide spectrum of disciplines and expertise, including protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. Nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.

LetsGetChecked is an at-home health testing platform that connects customers to regulated laboratory testing to better manage and control one's individual health. LetsGetChecked is making healthcare and diagnostics open and patient-led, empowering people to use technology in a simple yet powerful way. This offers consumers greater control over their individual health. LetsGetChecked is headquartered in New York, NY, with tests covering general wellness, sexual health, women's health and men's health, and is available nationwide, as well as in Canada and Europe.

Vedere is developing cutting-edge gene therapy products to restore functional vision to patients who have suffered vision loss from Inherited Retinal Degenerations (IRDs), as well as other causes of both genetic and non-genetic vision loss. While the vast majority of ocular gene therapies only limit the rate of inevitable vision loss, we aim to restore lost vision regardless of a patient’s underlying genetics or their stage of disease.

Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.

Dyno Therapeutics Inc. specializes in the development of adeno-associated virus (AAV) vectors for in vivo delivery of gene therapies. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes an artificial intelligence-driven approach that integrates DNA synthesis, sequencing, and machine learning. This innovative methodology enables the design of novel gene vectors with an emphasis on cell-targeting capsid proteins derived from AAV, which is recognized as the most commonly used vector in gene therapy applications. By leveraging quantitative high-throughput in vivo experimentation, Dyno Therapeutics aims to enhance the effectiveness and precision of gene therapy solutions.

Apton Biosystems develops a high-throughput and low-cost sequencing platform that revolutionizes the availability of genetic analysis. It enables biomarker discovery, early disease detection, and therapeutic monitoring, advancing preventive health and precision medicine.

Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug design, surpassing conventional human endeavor. Their AI-driven systems actively learn best practice from vast repositories of discovery data and are further enhanced with knowledge acquired from seasoned drug hunters. With better information to hand than any researcher could acquire individually, their knowledge-driven systems design millions of novel, project-specific compounds and pre-assess each for predicted potency, selectivity, ADME and other key criteria. From this, a selection of the best, information-rich compounds are selected for synthesis and assay. With new experimental data generated, the results are integrated and the next design cycle initiated. Rapid design-make-test cycles ensure unparalleled progress towards desired project goals. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches.

Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions. The company was founded in 2021 and is headquartered in Stamford, CT.

C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The company's ultra-sensitive liquid biopsy assay will allow physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods.

Multiply Labs manufactures personalized pharmaceutical capsules that are tailor-made to the unique needs of each patient. Multiply Labs’ product is enabled by the combination of pharmaceutical science with robotics technology. The company has built and operates a unique robotic pharmaceutical manufacturing facility. Multiply Labs is the first company ever to bring to the market 3D printed capsules.

Ventus Therapeutics U.S., Inc. is a biopharmaceutical company based in Natick, Massachusetts, with an additional location in Montreal, Canada. Founded in 2019, it focuses on discovering and developing novel small-molecule medicines that target the innate immune system to address autoimmune diseases, inflammatory diseases, and cancer. The company employs a structural immunology platform that integrates protein engineering to elucidate molecular structures and mechanisms of action. This platform facilitates the development of precise binding and functional screening assays, as well as structure-based modeling. Ventus Therapeutics is advancing an emerging pipeline of drug programs aimed at key targets within the innate immune system, leveraging its proprietary capabilities in rational and structure-based drug design.

SeQure DX is in the business activities at non-commercial site business. It was founded in 2020 and is based in Waltham, Massachusetts.

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

Komodo Health Inc. is a healthcare technology company that provides a platform for healthcare data aimed at enhancing decision-making and transparency in the industry. Founded in 2014 and headquartered in New York, with an additional office in San Francisco, the company offers various software applications, including Healthcare Map, which tracks patient outcomes across the healthcare system. Its solutions, such as Aperture, Pulse, and Serenity, deliver valuable insights by analyzing extensive data from patients, practitioners, and health systems. These applications enable health and life sciences enterprises to identify insights, address gaps in care, and reduce the burden of disease, thereby setting a new standard for real-world data and analytics in healthcare.

Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

Tenaya Therapeutics, Inc. develops therapeutics for heart failure. It offers cellular regeneration platform, that enables in vivo reprogramming of cardiac fibroblasts into cardio myocytes by delivering proprietary transcription factors; gene therapy platform, that enables the targeted delivery of a payload to cardiac fibroblasts ; and precision medicine platform, which provides personalized medicine approach to treat heart disease. The company was founded in 2016 and is headquartered in South San Francisco, California.

Notch Therapeutics Inc., an immune cell therapy company, develops gene-edited allogenic T cell therapies for the treatment of cancer. The company offers induced pluripotent stem cell (iPSC) AlloCAR therapy products for non-Hodgkin lymphoma, leukemia, and multiple myeloma. Notch Therapeutics Inc. was incorporated in 2018 and is based in Toronto, Canada.

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company’s gene therapy approach seeks to transform a patient’s hematopoietic stem cells into a gene-modified drug product to treat the patient’s disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company’s clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Imagen is a healthcare company whose mission is to save patient lives by making accurate medical image interpretation universally available and affordable. Currently, over two-thirds of the world’s population doesn’t have access to basic radiology services. Through our technology and close collaboration with world-leading clinicians, we believe that we can do something about it. We take an interdisciplinary approach: we are a team of experts in machine learning, healthcare, software engineering, and regulatory affairs who research and develop assistive software for clinicians. Our FDA-cleared software analyzes the content of medical images and produces diagnoses, improving the diagnostic accuracy of clinicians by highlighting detected pathology. We are advised by some of the world’s leading scientists and medical researchers, including Turing Award winner Yann LeCun. We have raised over $60M from leading investors including GV, DFJ, and Zach Weinberg. Imagen is based in New York and actively hiring. Are you excited about joining our mission? Reach out directly to us at recruitingteam@imagen.ai

Auron Therapeutics is to develop therapies to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing, to transformation of malignant cells into normal cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and the transition from cancer to normal tissue. Its unique platforms allow for integration of large-omic datasets and miniaturized high throughput flow cytometry to rapidly identify and validate multiple targets and drugs in primary human patient samples.

Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing precision genetic medicines for serious diseases. It utilizes its proprietary base editing technology, which allows for targeted modifications at the single base level in the genome without causing double-stranded breaks in DNA. Beam's therapeutic pipeline includes treatments for sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder 1A, and various ocular and central nervous system disorders. The company aims to provide long-lasting cures through its innovative approaches, which include gene correction, gene modification, gene activation, gene silencing, and multiplex editing. Beam Therapeutics was founded in 2017 and is committed to advancing the field of genetic medicine through research and clinical collaborations, including a partnership with Magenta Therapeutics.

Paige builds software to advance the diagnosis, treatment, and biomarker discovery for cancer. The Memorial Sloan Kettering spin-out aims to help pathologists and clinicians make faster, more informed diagnostic and treatment decisions and to bring new digital biomarkers to their practice. Paige’s proprietary Machine Learning solutions provide insights from decades of data from the world’s experts in cancer care and were recently published in Nature Medicine. The company’s first product for prostate cancer detection received Breakthrough Designation from the FDA as a novel therapy that stands to improve diagnostic accuracy while reducing costs to health systems.

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before. The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

FogPharma is a healthcare company founded in 2015 and headquartered in Gloucester, Massachusetts. The firm is dedicated to the pharmaceutical sector, with a primary focus on developing innovative treatments for cancer. It operates with the support of a diverse group of private and institutional investors, fostering collaboration among its founders, employees, and advisors. FogPharma aims to create a new class of medicines designed to extend and enhance the lives of cancer patients. The company's commitment to its mission drives its efforts to pioneer effective solutions in cancer treatment.

Octave Bioscience is an early-stage molecular diagnostics company focused on neurodegenerative diseases and conditions. The company was co-founded by Melinda Thomas and William Hagstrom in 2013. Octave Bioscience is headquartered in Menlo Park, California, United States.

Faze Medicines, a pharmaceutical company, develops interventions against driver of disease pathology. It develops small molecule drugs for initial therapeutic focus areas, such as amyotrophic lateral sclerosis and myotonic dystrophy type 1. The company was founded in 2020 and is based in Cambridge, Massachusetts.

CANbridge Pharma is a biopharmaceutical company focused on the development and commercialization of healthcare products in China and North Asia, particularly for oncology and rare diseases. Established in 2012 and headquartered in Beijing, with additional offices in Shanghai, Cambridge, Taipei, and Hong Kong, the company partners with Western biopharmaceutical firms to bring clinical-stage pharmaceutical, medical device, and diagnostic products to the region. CANbridge specializes in therapies for serious medical conditions that are either unavailable or inadequately addressed in North Asia. Its key product, CAN008, is a glycosylated CD95-Fc fusion protein aimed at treating glioblastoma multiforme, while the company also has a diverse pipeline of biologics and small molecules targeting conditions such as Hunter Syndrome, hemophilia A, and various rare metabolic disorders. Through licensing and exclusive commercialization agreements, CANbridge seeks to enhance healthcare solutions for underserved patient populations in the region.

iVexSol Inc. is a biotechnology company specializing in the development of lentiviral vector (LVV) manufacturing technology aimed at addressing the shortage of these crucial gene delivery vehicles. Established in 2018 and located in Worcester, Massachusetts, iVexSol focuses on streamlining the manufacturing process for cell and gene therapies (CGTs). The company’s innovative technology simplifies the creation of essential reagents, significantly reducing development time and complexity. This advancement not only accelerates the development of CGTs but also enhances access for researchers and manufacturers in the field.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

AbSci, LLC is a biotechnology company based in Portland, Oregon, specializing in protein production technologies for the biopharmaceutical industry. Founded in 2011, AbSci has developed SoluPro, an innovative expression system utilizing genetically engineered E. coli to facilitate the scalable and cost-effective production of antibodies, antibody fragments, and other soluble recombinant proteins. This technology significantly lowers production costs for both novel and existing biologics, enhancing the efficiency of drug discovery and manufacturing processes. AbSci's therapeutic proteins and antibodies play vital roles in treatments for cancer, hormone-related conditions, autoimmune diseases, and blood disorders. The company's approach integrates biologic drug discovery with cell line development, positioning it as a leader in the advancement of next-generation therapeutics.

Cedilla is a developer of therapeutics technologies intended to broaden the reach of small molecule therapeutics. The company's technology is focused on destabilizing oncoprotein targets that are also applicable to therapies outside of oncology, enabling doctors to treat diseases caused by protein dysregulation. The company was founded in 2018 and based in Cambridge, Massachusetts.

Vineti is a commercial cloud-based platform that expands patient access to life-saving cells and gene therapies. The software solution offers an independent, purpose-built enterprise solution that is essential for enabling the growth and wide distribution of transformative personalized therapeutics, such as CAR-T cell therapies, for the treatment of late-stage cancer. The Vineti Personalized Therapy Management (PTM) ® platform automates patient-centric supply chains for a wide range of advanced therapies, in all phases of clinical development and commercial operations. Veneti aims to solve the key challenges patients, medical providers, pharmaceutical companies, and regulators face in the delivery and commercialization of personalized medicine. Amy DuRoss, Heidi M. Hagen, Malek Faham, Razmik Abnous, and Stephen Ting co-founded Vineti in San Francisco, California in 2016.

Oxford Nanopore Technologies Limited specializes in the development and commercialization of nanopore-based electronic systems for the analysis of single molecules, particularly in the fields of DNA and RNA sequencing. The company offers a range of products, including the portable MinION device for molecular analysis, the benchtop PromethION for large-scale sequencing projects, and the GridION system suitable for various molecular sensing applications. Their technology supports diverse scientific research areas such as genomics, cancer studies, microbiology, and environmental research, with applications extending to healthcare, agriculture, and food safety. The Flongle device caters to on-demand sequencing needs, while the MinIT accessory enhances the functionality of their sequencing devices. Oxford Nanopore’s innovative technology emphasizes accessibility and ease of use, with rapid library preparation and automated processes. Founded in 2005 and headquartered in Oxford, United Kingdom, the company operates additional offices worldwide, enabling its products to be utilized in over 80 countries.

A2 Biotherapeutics is an early-stage biotechnology company located in Southern California that develops novel medicines for serious illnesses. We utilize an advanced targeting technology platform to increase the effectiveness of the body’s natural immune defenses.

Invetx, Inc. is a biotechnology company based in Boston, Massachusetts, that specializes in developing protein-based therapeutics for animal health care. The company focuses on creating biopharmaceutical solutions that apply human biotechnology advancements to veterinary medicine. Invetx aims to build a premier innovation platform for veterinary therapeutics, collaborating with leading biotechnology firms, investors, and industry experts. Its team, which includes veterinary scientists and clinicians, is dedicated to discovering and developing a diverse portfolio of therapies and technologies. The company's vision is to enhance health outcomes for both pets and farm animals by leveraging biopharma technologies in the global animal health industry.

Monte Rosa Therapeutics is a biotechnology company based in Basel, Switzerland, that specializes in developing innovative cancer therapeutics through the modulation of protein degradation pathways. The company focuses on molecular glue degraders (MGDs), a class of small molecule drugs that utilize the body's natural mechanisms for protein degradation to selectively target and degrade proteins relevant to cancer treatment. Monte Rosa employs its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, to identify and develop target proteins for degradation. With a library of over 50,000 MGD molecules, its leading product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing potential for treating MYC-driven tumors. The company is committed to advancing its pipeline of novel therapeutics to address unmet medical needs in oncology.

NiKang Therapeutics, Inc. is a biotechnology company established in 2017 and located in Wilmington, Delaware. The company is dedicated to discovering and developing innovative small molecule oncology medicines aimed at addressing unmet medical needs in cancer treatment. By employing a discovery approach that leverages target structure biology and structure-based drug design, NiKang Therapeutics aims to facilitate the rapid and efficient development of proprietary drug candidates with optimal pharmacological properties. The company seeks to enhance the treatment options available to healthcare providers, ultimately improving patient outcomes in the fight against cancer.

Oxford NanoImaging Limited develops and manufactures microscope. It offers Nanoimager, a single-molecule fluorescence microscope which enables researchers to detect biomolecules, such as protein markers for disease or pathogenic bacteria, and viruses at single copy numbers with single-molecule imaging, 3D, and dual-color super-resolution functionality. It also offers Förster Resonance Energy Transfer microscopy technology that reports distances in real time; direct stochastic optical reconstruction microscopy (dSTORM); and photoactivated localization microscopy (PALM) technology based microscope. Oxford NanoImaging Limited was incorporated in 2016 and is based in London, United Kingdom. The company has additional office in Menlo Park, California.

Lyra helps companies improve access to effective, high-quality mental health care for their employees. Lyra's matching technology and innovative digital platform connect members to a curated network of top therapists and coaches, which results in 3x more people receiving care and 7x better outcomes than traditional plans and EAPs. Members can find the right personalized care, match with the right provider for their needs, and feel motivated and supported throughout the entire treatment journey.

Tango Therapeutics, Inc., a biotechnology company, develops cancer drugs based on synthetic lethality. The company uses the genetic principle of synthetic lethality to discover and develop therapies that take aim at driver genes in cancer. It focuses counteracting tumor suppressor gene loss; reversing the ability of cancer cells to evade the immune system; and identifying novel combinations that are more effective than single agent therapy. Tango Therapeutics, Inc. was formerly known as Cancer Combos NewCo, Inc. The company was incorporated in 2014 and is based in Cambridge, Massachusetts.

DNA Script is a disruptive DNA synthesis company engineering biology to accelerate breakthroughs in life science and human health. Our revolutionary enzymatic technology powers the world's first benchtop DNA printer, SYNTAX, enabling labs to print their own synthetic oligos for greater workflow control and faster access to results.

GeneMatters delivers genetic counseling services for hospitals, health networks, clinics, academic research centers, and genetic testing labs. The company is the operator of an online genetic counseling network intended for providing genetic counseling and caregiving services. The company's genetic counseling network facilitates pre-test counseling, full-service genetic counseling, and caregiving services for people seeking genetic insights, enabling users in understanding their genetic family history and make informed decisions based on genetic tests. GeneMatters was established in 2016 and is based in Minneapolis, Minnesota, United States.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company dedicated to discovering and developing precision therapies for kidney diseases. The company focuses on researching and commercializing treatments for conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Notable programs include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio is also developing the Kidney Genome Atlas, a genomic registry aimed at identifying new disease targets and biomarkers, and utilizes a biology platform that leverages stem cell science to create human organoid models for target validation. Founded in 2016 and based in Cambridge, Massachusetts, Goldfinch Bio has established a strategic collaboration with Gilead Sciences to enhance its capabilities in kidney disease therapy development.

Verve Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies aimed at editing the adult human genome to reduce the risk of coronary artery disease, a leading cause of death globally. Founded in 2018 and headquartered in Cambridge, Massachusetts, with a research facility in Philadelphia, the company leverages human genetic analysis and gene-editing technologies to create treatments that offer lifelong protection from this condition. Verve has established strategic alliances, including collaborations with Beam Therapeutics to advance delivery technologies targeting cardiovascular issues and with Verily for developing gene editing delivery vehicles. Formerly known as Endcadia, Verve Therapeutics rebranded in September 2019 to reflect its commitment to addressing heart disease through advanced genetic solutions.

C2i Genomics provides cloud-based cancer diagnostic services to pharmaceutical and diagnostic organizations. The company's ultra-sensitive liquid biopsy assay will allow physicians to monitor patient treatment response and detect treatment failure or disease recurrence months and potentially years earlier than current monitoring methods.

Insitro is a operator of a data-driven drug discovery and development company that uses machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company uses state-of-the-art technologies from Bioengineering enabling it to generate high-throughput, functional genomic data sets and aligning them with patient data via a novel machine learning methods, thereby building predictive models that can accelerate target selection and the design and development of effective therapeutics.

MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.